Escape of the response to a long-acting somatostatin analogue (SMS 201–995) in patients with VIPoma
Two patients with severe secretory diarrhea due to metastatic vasoactive intestinal peptidoma were treated with a synthetic somatostatin analogue in an attempt to control the patients' vasoactive intestinal peptide-related symptoms. In both patients, a good initial response to this treatment co...
Gespeichert in:
| Veröffentlicht in: | Gastroenterology (New York, N.Y. 1943) N.Y. 1943), 1987-02, Vol.92 (2), p.527-531 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 531 |
|---|---|
| container_issue | 2 |
| container_start_page | 527 |
| container_title | Gastroenterology (New York, N.Y. 1943) |
| container_volume | 92 |
| creator | Koelz, Annemarie Kraenzlin, Marius Gyr, Klaus Meier, Verena Bloom, Stephen R. Heitz, Philipp Stalder, Hans |
| description | Two patients with severe secretory diarrhea due to metastatic vasoactive intestinal peptidoma were treated with a synthetic somatostatin analogue in an attempt to control the patients' vasoactive intestinal peptide-related symptoms. In both patients, a good initial response to this treatment could be demonstrated; not only did diarrhea subside but there was also a dramatic fall in vasoactive intestinal peptide plasma levels. However, after 11 and 4 days respectively, diarrhea recurred accompanied by a rise in vasoactive intestinal peptide plasma levels. In fact, under treatment with the somatostatin analogue and with natural somatostatin, a significant rebound state was observed regarding diarrhea as well as vasoactive intestinal peptide levels, which caused considerable difficulty in the clinical management in 1 patient. This patient had to undergo surgery. In the second patient, the responsiveness to somatostatin analogue returned a few days after discontinuation of the treatment, lasting, however, for a short period only. The possible mechanism of this escape and rebound with somatostatin treatment is discussed. |
| doi_str_mv | 10.1016/0016-5085(87)90153-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77364259</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0016508587901533</els_id><sourcerecordid>77364259</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-b4bc975197afd0ea7928c89a61a1fe5f6c97df289a723bae9090fa9bde90e5413</originalsourceid><addsrcrecordid>eNp9kM-KFDEQh4Mo67j6Bgo5iOweWvOn00kugiyrLqworHoN1enKbEtPpzfJKN58B9_QJzHjDHP0kqTy-6oSPkKecvaSM969YnVpFDPqzOhzy7iSjbxHVlwJ09RM3CerI_KQPMr5G2PMSsNPyIkw2hilVwQvs4cFaQy03CJNmJc4Z6QlUqBTnNcN-DLOa5rjBkrMBWpFYYYprrdIz24-3FDB-J9fv61V57RmSyVwLpn-GMst_Xr1qTY-Jg8CTBmfHPZT8uXt5eeL9831x3dXF2-uGy9NV5q-7b3VilsNYWAI2grjjYWOAw-oQlfTIYh6o4XsAS2zLIDth3pC1XJ5Sl7s5y4p3m0xF7cZs8dpghnjNjutZdcKZSvY7kGfYs4Jg1vSuIH003HmdnbdTp3bqXNGu392naxtzw7zt_0Gh2PTQWfNnx9yqFqnkGD2Yz5iRrai63avv95jWF18HzG57Kszj8OY0Bc3xPH___gL0vmVqA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>77364259</pqid></control><display><type>article</type><title>Escape of the response to a long-acting somatostatin analogue (SMS 201–995) in patients with VIPoma</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><source>Alma/SFX Local Collection</source><creator>Koelz, Annemarie ; Kraenzlin, Marius ; Gyr, Klaus ; Meier, Verena ; Bloom, Stephen R. ; Heitz, Philipp ; Stalder, Hans</creator><creatorcontrib>Koelz, Annemarie ; Kraenzlin, Marius ; Gyr, Klaus ; Meier, Verena ; Bloom, Stephen R. ; Heitz, Philipp ; Stalder, Hans</creatorcontrib><description>Two patients with severe secretory diarrhea due to metastatic vasoactive intestinal peptidoma were treated with a synthetic somatostatin analogue in an attempt to control the patients' vasoactive intestinal peptide-related symptoms. In both patients, a good initial response to this treatment could be demonstrated; not only did diarrhea subside but there was also a dramatic fall in vasoactive intestinal peptide plasma levels. However, after 11 and 4 days respectively, diarrhea recurred accompanied by a rise in vasoactive intestinal peptide plasma levels. In fact, under treatment with the somatostatin analogue and with natural somatostatin, a significant rebound state was observed regarding diarrhea as well as vasoactive intestinal peptide levels, which caused considerable difficulty in the clinical management in 1 patient. This patient had to undergo surgery. In the second patient, the responsiveness to somatostatin analogue returned a few days after discontinuation of the treatment, lasting, however, for a short period only. The possible mechanism of this escape and rebound with somatostatin treatment is discussed.</description><identifier>ISSN: 0016-5085</identifier><identifier>EISSN: 1528-0012</identifier><identifier>DOI: 10.1016/0016-5085(87)90153-3</identifier><identifier>PMID: 2878857</identifier><identifier>CODEN: GASTAB</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Adenoma, Islet Cell - drug therapy ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Female ; Hormones. Endocrine system ; Humans ; Male ; Medical sciences ; Middle Aged ; Octreotide ; Pancreatic Neoplasms - drug therapy ; Pharmacology. Drug treatments ; Somatostatin - analogs & derivatives ; Somatostatin - therapeutic use ; Time Factors ; Vasoactive Intestinal Peptide - blood ; Vipoma - drug therapy</subject><ispartof>Gastroenterology (New York, N.Y. 1943), 1987-02, Vol.92 (2), p.527-531</ispartof><rights>1987</rights><rights>1987 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c386t-b4bc975197afd0ea7928c89a61a1fe5f6c97df289a723bae9090fa9bde90e5413</citedby><cites>FETCH-LOGICAL-c386t-b4bc975197afd0ea7928c89a61a1fe5f6c97df289a723bae9090fa9bde90e5413</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0016-5085(87)90153-3$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3549,27923,27924,45994</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=8342669$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2878857$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Koelz, Annemarie</creatorcontrib><creatorcontrib>Kraenzlin, Marius</creatorcontrib><creatorcontrib>Gyr, Klaus</creatorcontrib><creatorcontrib>Meier, Verena</creatorcontrib><creatorcontrib>Bloom, Stephen R.</creatorcontrib><creatorcontrib>Heitz, Philipp</creatorcontrib><creatorcontrib>Stalder, Hans</creatorcontrib><title>Escape of the response to a long-acting somatostatin analogue (SMS 201–995) in patients with VIPoma</title><title>Gastroenterology (New York, N.Y. 1943)</title><addtitle>Gastroenterology</addtitle><description>Two patients with severe secretory diarrhea due to metastatic vasoactive intestinal peptidoma were treated with a synthetic somatostatin analogue in an attempt to control the patients' vasoactive intestinal peptide-related symptoms. In both patients, a good initial response to this treatment could be demonstrated; not only did diarrhea subside but there was also a dramatic fall in vasoactive intestinal peptide plasma levels. However, after 11 and 4 days respectively, diarrhea recurred accompanied by a rise in vasoactive intestinal peptide plasma levels. In fact, under treatment with the somatostatin analogue and with natural somatostatin, a significant rebound state was observed regarding diarrhea as well as vasoactive intestinal peptide levels, which caused considerable difficulty in the clinical management in 1 patient. This patient had to undergo surgery. In the second patient, the responsiveness to somatostatin analogue returned a few days after discontinuation of the treatment, lasting, however, for a short period only. The possible mechanism of this escape and rebound with somatostatin treatment is discussed.</description><subject>Adenoma, Islet Cell - drug therapy</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Female</subject><subject>Hormones. Endocrine system</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Octreotide</subject><subject>Pancreatic Neoplasms - drug therapy</subject><subject>Pharmacology. Drug treatments</subject><subject>Somatostatin - analogs & derivatives</subject><subject>Somatostatin - therapeutic use</subject><subject>Time Factors</subject><subject>Vasoactive Intestinal Peptide - blood</subject><subject>Vipoma - drug therapy</subject><issn>0016-5085</issn><issn>1528-0012</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1987</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM-KFDEQh4Mo67j6Bgo5iOweWvOn00kugiyrLqworHoN1enKbEtPpzfJKN58B9_QJzHjDHP0kqTy-6oSPkKecvaSM969YnVpFDPqzOhzy7iSjbxHVlwJ09RM3CerI_KQPMr5G2PMSsNPyIkw2hilVwQvs4cFaQy03CJNmJc4Z6QlUqBTnNcN-DLOa5rjBkrMBWpFYYYprrdIz24-3FDB-J9fv61V57RmSyVwLpn-GMst_Xr1qTY-Jg8CTBmfHPZT8uXt5eeL9831x3dXF2-uGy9NV5q-7b3VilsNYWAI2grjjYWOAw-oQlfTIYh6o4XsAS2zLIDth3pC1XJ5Sl7s5y4p3m0xF7cZs8dpghnjNjutZdcKZSvY7kGfYs4Jg1vSuIH003HmdnbdTp3bqXNGu392naxtzw7zt_0Gh2PTQWfNnx9yqFqnkGD2Yz5iRrai63avv95jWF18HzG57Kszj8OY0Bc3xPH___gL0vmVqA</recordid><startdate>19870201</startdate><enddate>19870201</enddate><creator>Koelz, Annemarie</creator><creator>Kraenzlin, Marius</creator><creator>Gyr, Klaus</creator><creator>Meier, Verena</creator><creator>Bloom, Stephen R.</creator><creator>Heitz, Philipp</creator><creator>Stalder, Hans</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19870201</creationdate><title>Escape of the response to a long-acting somatostatin analogue (SMS 201–995) in patients with VIPoma</title><author>Koelz, Annemarie ; Kraenzlin, Marius ; Gyr, Klaus ; Meier, Verena ; Bloom, Stephen R. ; Heitz, Philipp ; Stalder, Hans</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-b4bc975197afd0ea7928c89a61a1fe5f6c97df289a723bae9090fa9bde90e5413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1987</creationdate><topic>Adenoma, Islet Cell - drug therapy</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Female</topic><topic>Hormones. Endocrine system</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Octreotide</topic><topic>Pancreatic Neoplasms - drug therapy</topic><topic>Pharmacology. Drug treatments</topic><topic>Somatostatin - analogs & derivatives</topic><topic>Somatostatin - therapeutic use</topic><topic>Time Factors</topic><topic>Vasoactive Intestinal Peptide - blood</topic><topic>Vipoma - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Koelz, Annemarie</creatorcontrib><creatorcontrib>Kraenzlin, Marius</creatorcontrib><creatorcontrib>Gyr, Klaus</creatorcontrib><creatorcontrib>Meier, Verena</creatorcontrib><creatorcontrib>Bloom, Stephen R.</creatorcontrib><creatorcontrib>Heitz, Philipp</creatorcontrib><creatorcontrib>Stalder, Hans</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Gastroenterology (New York, N.Y. 1943)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Koelz, Annemarie</au><au>Kraenzlin, Marius</au><au>Gyr, Klaus</au><au>Meier, Verena</au><au>Bloom, Stephen R.</au><au>Heitz, Philipp</au><au>Stalder, Hans</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Escape of the response to a long-acting somatostatin analogue (SMS 201–995) in patients with VIPoma</atitle><jtitle>Gastroenterology (New York, N.Y. 1943)</jtitle><addtitle>Gastroenterology</addtitle><date>1987-02-01</date><risdate>1987</risdate><volume>92</volume><issue>2</issue><spage>527</spage><epage>531</epage><pages>527-531</pages><issn>0016-5085</issn><eissn>1528-0012</eissn><coden>GASTAB</coden><abstract>Two patients with severe secretory diarrhea due to metastatic vasoactive intestinal peptidoma were treated with a synthetic somatostatin analogue in an attempt to control the patients' vasoactive intestinal peptide-related symptoms. In both patients, a good initial response to this treatment could be demonstrated; not only did diarrhea subside but there was also a dramatic fall in vasoactive intestinal peptide plasma levels. However, after 11 and 4 days respectively, diarrhea recurred accompanied by a rise in vasoactive intestinal peptide plasma levels. In fact, under treatment with the somatostatin analogue and with natural somatostatin, a significant rebound state was observed regarding diarrhea as well as vasoactive intestinal peptide levels, which caused considerable difficulty in the clinical management in 1 patient. This patient had to undergo surgery. In the second patient, the responsiveness to somatostatin analogue returned a few days after discontinuation of the treatment, lasting, however, for a short period only. The possible mechanism of this escape and rebound with somatostatin treatment is discussed.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>2878857</pmid><doi>10.1016/0016-5085(87)90153-3</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0016-5085 |
| ispartof | Gastroenterology (New York, N.Y. 1943), 1987-02, Vol.92 (2), p.527-531 |
| issn | 0016-5085 1528-0012 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77364259 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present); Alma/SFX Local Collection |
| subjects | Adenoma, Islet Cell - drug therapy Antineoplastic Agents - therapeutic use Biological and medical sciences Female Hormones. Endocrine system Humans Male Medical sciences Middle Aged Octreotide Pancreatic Neoplasms - drug therapy Pharmacology. Drug treatments Somatostatin - analogs & derivatives Somatostatin - therapeutic use Time Factors Vasoactive Intestinal Peptide - blood Vipoma - drug therapy |
| title | Escape of the response to a long-acting somatostatin analogue (SMS 201–995) in patients with VIPoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T14%3A11%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Escape%20of%20the%20response%20to%20a%20long-acting%20somatostatin%20analogue%20(SMS%20201%E2%80%93995)%20in%20patients%20with%20VIPoma&rft.jtitle=Gastroenterology%20(New%20York,%20N.Y.%201943)&rft.au=Koelz,%20Annemarie&rft.date=1987-02-01&rft.volume=92&rft.issue=2&rft.spage=527&rft.epage=531&rft.pages=527-531&rft.issn=0016-5085&rft.eissn=1528-0012&rft.coden=GASTAB&rft_id=info:doi/10.1016/0016-5085(87)90153-3&rft_dat=%3Cproquest_cross%3E77364259%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=77364259&rft_id=info:pmid/2878857&rft_els_id=0016508587901533&rfr_iscdi=true |